Marrone Bio Innovations (MBII) Getting Somewhat Favorable News Coverage, Analysis Finds

News articles about Marrone Bio Innovations (NASDAQ:MBII) have been trending somewhat positive on Tuesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Marrone Bio Innovations earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the basic materials company an impact score of 45.0636246115923 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of Marrone Bio Innovations (MBII) traded down 1.82% on Tuesday, reaching $1.08. The company had a trading volume of 83,075 shares. Marrone Bio Innovations has a 52 week low of $0.85 and a 52 week high of $2.79. The company’s 50-day moving average price is $1.13 and its 200 day moving average price is $1.39. The firm’s market capitalization is $33.86 million.

Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Monday, August 14th. The basic materials company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). The business had revenue of $6.48 million during the quarter, compared to the consensus estimate of $6.62 million. On average, analysts expect that Marrone Bio Innovations will post ($1.01) EPS for the current year.

Several research analysts recently weighed in on the company. ValuEngine cut Marrone Bio Innovations from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. HC Wainwright set a $4.00 price target on Marrone Bio Innovations and gave the company a “buy” rating in a research report on Tuesday, August 15th. Piper Jaffray Companies set a $1.00 price target on Marrone Bio Innovations and gave the company a “hold” rating in a research report on Saturday, July 22nd. Finally, Zacks Investment Research upgraded Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. Marrone Bio Innovations has an average rating of “Hold” and a consensus target price of $2.50.

ILLEGAL ACTIVITY NOTICE: “Marrone Bio Innovations (MBII) Getting Somewhat Favorable News Coverage, Analysis Finds” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/19/marrone-bio-innovations-mbii-getting-somewhat-favorable-news-coverage-analysis-finds.html.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Insider Buying and Selling by Quarter for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply